{"id":"W2947217282","doi":"10.1200/jco.2019.37.15_suppl.1002","title":"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":100,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Capecitabine; Medicine; Lapatinib; Internal medicine; Neratinib; Metastatic breast cancer; Gastroenterology; Clinical endpoint; Randomized controlled trial; Breast cancer; Oncology; Cancer; Trastuzumab; Colorectal cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002460904,0.0003916167,0.003424101,0.0001751736,0.00007234904,0.00002299942,0.0002290815,0.000242123,0.002798354],"category_scores_gemma":[0.001183989,0.0001960187,0.0004368319,0.0004534941,0.0003798391,0.000207971,0.00003642311,0.001107306,0.00001758589],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000484048,"about_ca_system_score_gemma":0.001871654,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001308275,"about_ca_topic_score_gemma":0.001727598,"domain_scores_codex":[0.9941281,0.001596532,0.00271969,0.0004352487,0.0007051748,0.0004152447],"domain_scores_gemma":[0.9858708,0.01004412,0.002432682,0.0002814739,0.001051694,0.0003192382],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8797773,0.01037635,0.09410197,0.00001695806,0.003344326,0.0001974991,0.0003515355,0.0000700431,0.00002533452,0.000009401588,0.003600608,0.008128633],"study_design_scores_gemma":[0.8693618,0.03152009,0.09092001,0.0002866271,0.003263044,0.00004312905,0.000113008,0.0003943684,0.00001960891,0.000008648581,0.003873105,0.0001966375],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9871031,0.0005753039,0.000006867646,0.007186586,0.001231321,0.003318217,0.0001009392,0.00002391319,0.0004537577],"genre_scores_gemma":[0.9942057,0.0005614221,0.001380807,0.00159586,0.0009124795,0.0002091486,0.000174237,0.00005172741,0.0009085846],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02114373,"threshold_uncertainty_score":0.9981132,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05348833309670203,"score_gpt":0.4172062872084293,"score_spread":0.3637179541117273,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}